Consequently, mutein should be advantageous in the treatment of those cancer diseases where the Treg expansion is relevant; in these settings, we expect better efficacy and lower percentages of non-responder patients due to lower levels of ICOS+Treg proliferation. This evidence concerns the gene ICOS and cancer.